oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciencesoncotomsk-240Research ArticleОБЗОРЫREVIEWSСОВРЕМЕНЫЕ ПРИНЦИПЫ КОМПЛЕКСНОГО ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (ОБЗОР ЛИТЕРАТУРЫ И АНАЛИЗ СОБСТВЕНОГО МАТЕРИАЛА)Current aspects of comprehensive treatmentfor advanced breast cancer (literature review and analysis of original material)ПакД. Д.PakD. D.БолотинаЛ. В.BolotinaL. V.СухотькоА. С.SuhotkoA. S.a.s.sykhotko@mail.ruФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена», г. МоскваРоссияP.A. Gertsen Moscow Research Institute of Oncology, MoscowRussian Federation201323022016055458Copyright © Пак Д.Д., Болотина Л.В., Сухотько А.С., 20162016Пак Д.Д., Болотина Л.В., Сухотько А.С.Pak D.D., Bolotina L.V., Suhotko A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/240

Обзор посвящен основным методам комплексного лечения генерализованного рака молочной железы. Проведен анализ международных исследований, целью которых явилась оценка эффективности хирургического лечения как этапа комплексного лечения больных раком молочной железы IV стадии. Рассмотрена роль современной лекарственной терапии как фактора, увеличивающего общую выживаемость

The review is devoted to the treatment methods for advanced breast cancer. The analysis of international studies aimed to assess the efficacy of surgical treatment for stage IV breast cancer patients was carried out. The role of the current drug therapy as a factor contributing to increase in the overall survival was studied

рак молочной железыкомплексное лечениеbreast cancercomprehensive treatmentReferencesБелохвостова А.С., Смирнова И.А., Енилеева А.А. Таргетная терапия в лечении HER2-позитивного рака молочной железы//Сибирский онкологический журнал. 2013. № 2 (56). С. 84-88Белохвостова А.С., Смирнова И.А., Енилеева А.А. Таргетная терапия в лечении HER2-позитивного рака молочной железы//Сибирский онкологический журнал. 2013. № 2 (56). С. 84-88Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 году. М., 2012. 260 сЧиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 году. М., 2012. 260 сAdam R., Aloia T., Krissat J. et al. Is liver resection justified for patients with hepatic metastases from breast cancer?//Ann. Surg. 2006. Vol. 244 (6). P. 897-907Adam R., Aloia T., Krissat J. et al. Is liver resection justified for patients with hepatic metastases from breast cancer?//Ann. Surg. 2006. Vol. 244 (6). P. 897-907Andre F., Slimane K., Bachelot T. et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period//J. Clin. Oncol. 2004. Vol. 22 (16). P. 3302-3308Andre F., Slimane K., Bachelot T. et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period//J. Clin. Oncol. 2004. Vol. 22 (16). P. 3302-3308Bafford A.C., Burstein H.J., Barkley C.R. et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival//Breast Cancer Res. Treat. 2009. Vol. 115 (1). P. 7-12Bafford A.C., Burstein H.J., Barkley C.R. et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival//Breast Cancer Res. Treat. 2009. Vol. 115 (1). P. 7-12Baum M., Demicheni R., Hrushesky W. et al. Does sugery unfavourably perturb the «natural history» of early breast cancer by accelerating the appearance of distant metastases?//Eur. J. Cancer. 2005. Vol. 41. P. 508-515Baum M., Demicheni R., Hrushesky W. et al. Does sugery unfavourably perturb the «natural history» of early breast cancer by accelerating the appearance of distant metastases?//Eur. J. Cancer. 2005. Vol. 41. P. 508-515Bathe O.F., Kaklamanos I.G., Moffat F.L. et al. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer//Surg. Oncol. 1999. Vol. 8 (1). P. 35-42Bathe O.F., Kaklamanos I.G., Moffat F.L. et al. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer//Surg. Oncol. 1999. Vol. 8 (1). P. 35-42Blanchard D.K., Shetty P.B., Hilsenbeck S.G. et al. Association of surgery with improved survival in stage IV breast cancer patients//Ann. Surg. 2008. Vol. 247 (5). P. 732-738Blanchard D.K., Shetty P.B., Hilsenbeck S.G. et al. Association of surgery with improved survival in stage IV breast cancer patients//Ann. Surg. 2008. Vol. 247 (5). P. 732-738Blazer D.G., Kishi Y., Maru D.M. et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases//J. Clin. Oncol. 2008. Vol. 26 (33). P. 5344-5351Blazer D.G., Kishi Y., Maru D.M. et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases//J. Clin. Oncol. 2008. Vol. 26 (33). P. 5344-5351Burzykowski T., Buyse M., Piccart-Gebhart M.J. et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer//J. Clin. Oncol. 2008. Vol. 26 (12). P. 1987-1992Burzykowski T., Buyse M., Piccart-Gebhart M.J. et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer//J. Clin. Oncol. 2008. Vol. 26 (12). P. 1987-1992Buzdar A.U., Blumenschein G.R., Smith T.L. et al. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)//J. Surg. Oncol. 1979. Vol. 12 (1). P. 27-40Buzdar A.U., Blumenschein G.R., Smith T.L. et al. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)//J. Surg. Oncol. 1979. Vol. 12 (1). P. 27-40Buyse M., Piccart-Gebhart M.J., Burzykowski T. et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer//J. Clin. Oncol. 2008. Vol. 26 (12). P. 1980-1986Buyse M., Piccart-Gebhart M.J., Burzykowski T. et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer//J. Clin. Oncol. 2008. Vol. 26 (12). P. 1980-1986Coffey J.C., Wang J. H., Smith M.J. Excisional surgery for cancer cure. Therapy at a cost//Lancer Oncol. 2003. Vol. 4. P. 760-768Coffey J.C., Wang J. H., Smith M.J. Excisional surgery for cancer cure. Therapy at a cost//Lancer Oncol. 2003. Vol. 4. P. 760-768Fields R.C., Jeffe D.B., Trinkaus K. et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site metastasis//Ann. Surg. Oncol. 2007. Vol. 14 (12). P. 3345-3351Fields R.C., Jeffe D.B., Trinkaus K. et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site metastasis//Ann. Surg. Oncol. 2007. Vol. 14 (12). P. 3345-3351Friedel G., Pastorino U., Ginsberg R.J. et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases//Eur. J. Cardiothorac. Surg. 2002. Vol. 22 (3). P. 335-344Friedel G., Pastorino U., Ginsberg R.J. et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases//Eur. J. Cardiothorac. Surg. 2002. Vol. 22 (3). P. 335-344Gnerlich J., Jeffe D.B., Deshpande A.D. et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data//Ann. Surg. Oncol. 2007. Vol. 14 (8). P. 2187-2194Gnerlich J., Jeffe D.B., Deshpande A.D. et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data//Ann. Surg. Oncol. 2007. Vol. 14 (8). P. 2187-2194Greenberg P.A., Hortobagyi G.N., Smith T.L. et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer//J. Clin. Oncol. 1996. Vol. 14 (8). P. 2197-2205Greenberg P.A., Hortobagyi G.N., Smith T.L. et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer//J. Clin. Oncol. 1996. Vol. 14 (8). P. 2197-2205Hackshaw A., Knight A., Barrett-Lee P. et al. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer//Br. J. Cancer. 2005. Vol. 93 (11). P. 1215-1221Hackshaw A., Knight A., Barrett-Lee P. et al. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer//Br. J. Cancer. 2005. Vol. 93 (11). P. 1215-1221Hanrahan E.O., Broglio K.R., Buzdar A.U. et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors//Cancer. 2005. Vol. 104 (6). P. 1158-1171Hanrahan E.O., Broglio K.R., Buzdar A.U. et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors//Cancer. 2005. Vol. 104 (6). P. 1158-1171Holmes F.A., Buzdar A.U., Kau S.W. et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED): the M.D. Anderson experience//Breast Dis. 1994. Vol. 7. P. 7-20Holmes F.A., Buzdar A.U., Kau S.W. et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED): the M.D. Anderson experience//Breast Dis. 1994. Vol. 7. P. 7-20Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy//Oncologist. 2006. Vol. 11. Suppl. 1. P. 34-41Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy//Oncologist. 2006. Vol. 11. Suppl. 1. P. 34-41Jakobs T.F., Hoffmann R.T., Schrader A. et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer//Cardiovasc. Interven. Radiol. 2009. Vol. 32 (1). P. 38-46Jakobs T.F., Hoffmann R.T., Schrader A. et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer//Cardiovasc. Interven. Radiol. 2009. Vol. 32 (1). P. 38-46Le Scodan R., Stevens D., Brian E. et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy//J. Clin. Oncol. 2009. Vol. 27 (9). P.137-138Le Scodan R., Stevens D., Brian E. et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy//J. Clin. Oncol. 2009. Vol. 27 (9). P.137-138Mahner S., Schirrmacher S., Brenner W. et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-Dglucose, conventional imaging and computed tomography for staging of breast cancer//Ann. Oncol. 2008. Vol. 19 (7). P.1249-1254Mahner S., Schirrmacher S., Brenner W. et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-Dglucose, conventional imaging and computed tomography for staging of breast cancer//Ann. Oncol. 2008. Vol. 19 (7). P.1249-1254Miksad R.A., Zietemann V., Gothe R. et al. Progression-free survival as a surrogate endpoint in advanced breast cancer//Int. J. Technol. Assess. Health Care. 2008. Vol. 24 (4). P. 371-383Miksad R.A., Zietemann V., Gothe R. et al. Progression-free survival as a surrogate endpoint in advanced breast cancer//Int. J. Technol. Assess. Health Care. 2008. Vol. 24 (4). P. 371-383Olson J.A., Marcom P.K. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer//Ann. Surg. 2008. Vol. 247 (5) P. 739-740Olson J.A., Marcom P.K. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer//Ann. Surg. 2008. Vol. 247 (5) P. 739-740O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer//Oncologist. 2005. Vol. 10 (3). P. 20-29O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer//Oncologist. 2005. Vol. 10 (3). P. 20-29Rapiti E., Verkooijen H.M., Vlastos G. et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis//J. Clin. Oncol. 2006. Vol. 24 (18). P. 2743-2749Rapiti E., Verkooijen H.M., Vlastos G. et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis//J. Clin. Oncol. 2006. Vol. 24 (18). P. 2743-2749Rena O., Papalia E., Ruffini E. et al. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients//Eur. J. Surg. Oncol. 2007. Vol. 33 (5). P. 546-550Rena O., Papalia E., Ruffini E. et al. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients//Eur. J. Surg. Oncol. 2007. Vol. 33 (5). P. 546-550Retsky M., Bonadonna G., Demicheli R. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients//Breast Cancer Res. 2004. Vol. 6 (4). P. 372-374Retsky M., Bonadonna G., Demicheli R. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients//Breast Cancer Res. 2004. Vol. 6 (4). P. 372-374Rivera E., Holmes F.A., Buzdar A.U. et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease//Breast J. 2002. Vol. 8 (1). P. 2-9Rivera E., Holmes F.A., Buzdar A.U. et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease//Breast J. 2002. Vol. 8 (1). P. 2-9Ruiterkamp J., Ernst M.F., van de Poll-Franse L.V. et al. Surgical resection of the primary tumor is associated with improved survival in patients with distant metastatic breast cancer at diagnosis//Eur. J. Surg. Oncol. 2009. Vol. 35 (11). P. 1146-1151Ruiterkamp J., Ernst M.F., van de Poll-Franse L.V. et al. Surgical resection of the primary tumor is associated with improved survival in patients with distant metastatic breast cancer at diagnosis//Eur. J. Surg. Oncol. 2009. Vol. 35 (11). P. 1146-1151Shien T., Kinoshita T., Shimizu C. et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer//Oncol. Rep. 2009. Vol. 21 (3). P. 827-832Shien T., Kinoshita T., Shimizu C. et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer//Oncol. Rep. 2009. Vol. 21 (3). P. 827-832Sinha P., Clements V.K., Miller S. et al. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression//Cancer Immunol. Immunother. 2005. Vol. 54 (11). P. 1137-1142Sinha P., Clements V.K., Miller S. et al. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression//Cancer Immunol. Immunother. 2005. Vol. 54 (11). P. 1137-1142Singletary S.E., Walsh G., Vauthey J.N. et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer//Oncologist. 2003. Vol. 8 (3). P. 241-251Singletary S.E., Walsh G., Vauthey J.N. et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer//Oncologist. 2003. Vol. 8 (3). P. 241-251Viadana E., Bross J., Pickren J. AmAutopsy Study of Some Routes of Dissemination of Cancer of the Breast//Br. J. Cancer. 1973. Vol. 27 (4). P. 336-340Viadana E., Bross J., Pickren J. AmAutopsy Study of Some Routes of Dissemination of Cancer of the Breast//Br. J. Cancer. 1973. Vol. 27 (4). P. 336-340

The authors declare that there are no conflicts of interest present.